I was going to save this post until beginning of November. But since we're kind of in a holding pattern for now, here's a glimpse of the remaining Q4 for Resverlogix and Zenith based upon posted events, abstract titles found on conference websites, information relayed to us via press releases, information relayed to us from corporate presentations, or dates extrapolated from trial start dates and my understanding of trial design. Disclaimer: None of this should be considered pumping. It is simply sharing actual or anticipated dates of events based on information in the public domain. Interpret this as you wish. There is no guarantee that any information shared at these events, or reaching a certain date, will positively or negatively impact the share price. Good things and bad things happen. Biotech stocks are risky. Do your own due diligence.
11/2: Zenith ZEN-3694 5th dosing level complete; start of 6th. ZEN-3694 dosing cycles based upon 28 day sequential cycles.
11/8: Resverlogix presents at BIO Europe
11/11: BETonMACE dosing reaches 12 months.
11/15: AGM (Zenith and Resverlogix) agenda anticipated to be released. From the RVX news release: "A notice of meeting and management information circular containing the matters to be considered at the meeting will be delivered to shareholders and filed on SEDAR at www.sedar.com on or before November 15, 2016."
11/15: Resverlogix presents at American Heart Association meeting. Title: Apabetalone (RVX-208) Reduces Expression of Acute Phase Response Markers in vitro and in Patients With Cardiovascular Disease.
11/18: Resverlogix presents at American Society for Nephrology/Kidney Week. Title: Apabetalone Reduces Levels of Key Markers Involved in Vascular Calcification. Also, Renal Clinical Advisory Board meets to finalize BETonDialysis Phase 2 study design, which is planned to launch early 2017.
11/30: Zenith presents at EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. Title: The investigational drug ZEN-3694, a novel BET-bromodomain inhibitor, inhibits multiple tumor immune escape mechanisms and has the potential to combine with immunotherapies.
11/30: Zenith ZEN-3694 6th dosing level complete; start of 7th
12/15 Resverlogix and Zenith AGMs
12/28: Zenith ZEN-3694 7th dosing level complete; start of 8th
Other potential 2016 issues/announcements/milestones based upon past company communications, new releases, presentations, or ongoing trials. There is no definitive date for any of these. Some of these may not happen until 2017 or might not ever happen at all. Biotech stocks are risky. Do your own due diligence.
Resverlogix:
Resverlogix Licensing Deal
Results of RVX-208 Phase 1 New Zealand Kidney Trial
Outcome of FDA meetings for BETonMACE and Renal
DSMB analysis at 12 months post start of BETonMACE dosing
Two new analysts
Two publications in progress
Officially confirm second clinical compound IND candidate
Zenith:
Zenith ZEN-3694 combo with enzalutamide trial begins (based upon previously presented timeline estimates)
ZenithZEN-3694 single agent trial update for safety/pharmacokinetic and potentially efficacy (based upon previously presented timeline estimates)
